Insider trade

Officer purchased ~$139K of DXCM shares in the open market

Traded Nov 10, 2025 · Filed Nov 11, 2025

DexcomDXCM

~$139K
Reported value · 2,500 sh @ $55.4252: 332K
Holds after · shares reported: +57.2%
stock since the trade · S&P 500 +12.1%, $54.84 → $86.23 on Oct 1

Why it stands out

Dexcom's President & COO spent $139K of their very own money to buy Dexcom shares.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 10, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 11, 2025

Officer$100K–$500KHoldings +1%

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$138,563

Shares × reported transaction price

Size band

$100K–$500K

Ownership change

+0.8%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

No other insider purchases within 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Size vs officer pay

This purchase equals about 2.5% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2024 ($5.62M)

An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-15. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement

Timing vs results

11 days after results of Oct 30, 2025, 63 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $54.84 on Nov 10, 2025, at its 52-week low, after a 17% drop over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $90.75 (Feb 24, 2025), 0% of the way up, from 250 adjusted closes. 30 trading days earlier: $66.46 on Sep 29, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Nov 10, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

5 such cases were open. Oakland County Employees Retirement System v. DexCom, Inc., docket 1:25-cv-09370, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+3.5%	-3.4%	+6.9%
30 days	+18.6%	+0.9%	+17.7%
90 days	+20.7%	+1.6%	+19.1%
180 days	+2.1%	+8.2%	-6.2%

Past results only. Not a forecast.

Source receipt

Record ID: 0001093557-25-000284
Filed / recorded: Nov 11, 2025, 12:13 AM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Jacob Steven Leach
Relationship: Officer
Officer title: President & COO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 10, 2025
Transaction code: P
Shares / units: 2,500
Price per share: $55.4252
Acquired / disposed: Acquired (A)
Shares owned after: 331,697
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was executed in multiple trades at prices ranging from $55.34 to $55.55. The price above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026.